Statistical analyses
REGRESSION, DECAY
For each individual in each trial a predicted neutralization titer on each day throughout follow-up was constructed as follows. The relationship between log10 mAb concentration of casirivimab + imdevimab and log10 pseudovirus neutralization titer was estimated using linear regression. For each participant in the COV-2069 trial, the slope from a linear regression of predicted log10 neutralization titer on days since injection was estimated over 8-months of follow-up. For the COVE antibody kinetics analysis, a hierarchical Bayesian model was used to estimate the posterior distribution of the rate of decay of the log neutralization titer, denoted B, over days 57, 119, and 209. The log10 neutralization titer on any day 